(Q46168564)

English

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

scientific article published on 8 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

(3aS)-palonosetron

1 reference

based on heuristic

inferred from title

0 references

author name string

Mitsue Saito

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Kenjiro Aogi

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Ikuo Sekine

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Hirohisa Yoshizawa

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Yasuhiro Yanagita

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Hiroshi Sakai

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Kenichi Inoue

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Chiyoe Kitagawa

8

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Takashi Ogura

9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Shoichi Mitsuhashi

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

publication date

8 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

115-124

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances in use of the 5-HT3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Are all 5-HT3 receptor antagonists the same?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiotoxicity of Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970313-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(08)70313-9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19135415

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46168564&oldid=2096472023"